GET DAILY SIGNALSCVRx (CVRX) Q3 Results Fall Short as Guidance Is Trimmed
Key Takeaways
- Third-quarter 2026 revenue came in at $13.8 million, below the roughly $13.94 million consensus estimate, while EPS was a loss of $0.52 versus the approximately $0.50 loss analysts expected.
- Full-year 2026 revenue guidance was lowered to a range of $56 million to $57 million, down from the prior $58 million to $60 million.
- Management guided fourth-quarter 2026 revenue of $11.7 million to $12.7 million and outlined plans to reduce its baseline cost structure.
- The company confirmed a CFO transition, with John Landry succeeding Jared Oasheim effective Nov. 6, 2026.
- For additional detail, explore CVRx's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- Discover automated market ideas by exploring Trending AI Robots.
Earnings Context and Why It Matters
CVRx is a commercial-stage medical device company focused on neuromodulation therapies for cardiovascular disease. Its flagship product, Barostim, is the first FDA-approved device that uses electrical pulses to the carotid baroreceptors to help improve symptoms in patients with heart failure. Because the company remains in an investment-heavy, pre-profitability phase, quarterly earnings are closely watched as a measure of commercial execution, reimbursement progress, and cash runway. Prior quarters showed solid U.S. revenue growth, but the third quarter marked a step back, with revenue declining year over year and management trimming its full-year outlook. This report is therefore important for gauging whether the company's growth trajectory is still intact amid broader reimbursement and operational pressures. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the third quarter of 2026 (the three months ended September 30, 2026), CVRx reported total revenue of $13.8 million, below the consensus estimate of roughly $13.94 million and down from $14.69 million in the prior-year period. The company posted a net loss of $0.52 per share, wider than the approximately $0.50 per-share loss analysts had expected, based on 27.2 million weighted-average shares outstanding.
Cash and cash equivalents stood at $58.7 million as of September 30, 2026. Net cash used in operating and investing activities was $11.0 million for the quarter, compared with $10.0 million in the same period a year earlier. The company also reduced its full-year 2026 revenue guidance to $56 million to $57 million from a prior range of $58 million to $60 million, while maintaining gross margin guidance of 86% to 87% and lowering operating expense guidance to $99 million to $101 million. For the fourth quarter of 2026, CVRx expects revenue between $11.7 million and $12.7 million.
Market Reaction and Investor Sentiment
Investor sentiment heading into the report was already cautious, with CVRx shares down roughly 79% year to date through early November, sharply underperforming the broader Nasdaq Composite. The third-quarter results reinforced those concerns, as revenue fell short of expectations and full-year guidance was reduced. In response, management outlined a comprehensive set of cost-reduction actions, including cuts in non-commercial functions while continuing to invest in sales and reimbursement teams, as well as disciplined hiring and a pullback on certain marketing and research and development projects. The simultaneous CFO transition adds another element for investors to evaluate as the company works to stabilize its operating model and cash position.
Forward Outlook and Key Factors to Monitor
Looking ahead, the lowered full-year guidance suggests management expects a more measured growth trajectory through the end of 2026. Investors will want to monitor whether the company can execute on its cost-reduction plan without weakening its commercial momentum in the United States, where expansion of sales territories and active implanting centers has been a key growth driver.
Reimbursement dynamics remain a central watch item. Earlier in the year, CVRx highlighted progress with the transition to Category I CPT codes, but also noted administrative friction around Medicare Advantage prior-authorization processes. How approval rates trend in coming quarters will be important for near-term revenue.
Longer term, the BENEFIT-HF clinical trial represents a major catalyst, as a successful outcome could significantly expand the eligible patient population for Barostim. Additionally, late-breaking data from the REBALANCE Registry presented at the HFSA scientific meeting, covering 435 patients across 45 U.S. centers, underscores the company's effort to build real-world clinical evidence. The newly appointed CFO's leadership and any further updates to cash management and cost discipline will also be closely watched. From what I see, this is important because it could shape the company's path in 2027 and beyond.
Using AI Tools in My Research
In my analysis of names like CVRx, I often rely on Tickeron’s AI Screener to quickly surface comparable companies in the medical device space and review key technical and fundamental metrics side by side. It helps me stay organized when tracking multiple names and sector trends without spending hours on manual screens.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CVRX's Indicator enters downward trend
The Aroon Indicator for CVRX entered a downward trend on October 27, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 201 similar instances where the Aroon Indicator formed such a pattern. In 184 of the 201 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 50 of 57 cases where CVRX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CVRX as a result. In 67 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CVRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CVRX's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Moving Average Convergence Divergence (MACD) for CVRX just turned positive on October 20, 2026. Looking at past instances where CVRX's MACD turned positive, the stock continued to rise in 41 of 46 cases over the following month. The odds of a continued upward trend are 89%.
Following a +15.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where CVRX advanced for three days, in 245 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
CVRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.160) is normal, around the industry mean (4.137). P/E Ratio (-0.441) is within average values for comparable stocks, (2.620). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.292) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. CVRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CVRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement